RT Book, Section
A1 Dopp, John M.
A1 Phillips, Bradley G.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1167752898
T1 Sleep–Wake Disorders
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1167752898
RD 2022/05/21
AB Content  UpdateSeptember  16,  2019Newly  Approved  Medication  for  Narcolepsy  with  or  without  Cataplexy:  The  U.S.  FDA  approved  a  medication  with  novel  mechanism  of  action  for  narcolepsy  treatment.  Pitolisant  (Wakix),  the  first  selective  histamine  3  (H3)  receptor  inverse  agonist,  was  approved  in  2019  for  narcolepsy.The  H3  receptor  inverse  agonist  was  approved  for  treating  excessive  daytime  sleepiness  (EDS)  in  narcolepsy  in  adults  because  of  its  hypothesized  role  in  increasing  wake-promoting  histamine.  While  other  treatments  for  EDS  are  available,  this  is  the  first  treatment  with  the  mechanism  of  action  involving  histamine.